WHO ICTRP trial
A Multi-center, Randomized, Double-blind, Positive Drug Parallel-controled Phase…
ChiCTR2200056471 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2200056471 |
|---|---|
| Public title | A Multi-center, Randomized, Double-blind, Positive Drug Parallel-controled Phase III Clinical Trial of Adamgammadex Sodium Reversing Rocuronium-Induced Neuromuscular Blockade at Three Consecutive PTC Counts of 1-2 in Adult Subjects Undergoing Elective Surgery |
| Scientific title | A Multi-center, Randomized, Double-blind, Positive Drug Parallel-controled Phase III Clinical Trial of Adamgammadex Sodium Reversing Rocuronium-Induced Neuromuscular Blockade at Three Consecutive PTC Counts of 1-2 in Adult Subjects Undergoing Elective Surgery |
| Primary sponsor | Shanghai Jiaotong Univercity School of Medicine, Renji Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 3 |
| Countries | China |
| Conditions | Reversal of Neuromuscular Blockade |
| Interventions | Experiment Group:Adamgammadex 8mg/kg;Control Group:Sugammadex 4mg/kg |
| Registration date | Feb 6, 2022 |
| Target size | Experiment Group:170;Control Group:170 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: